TRANSDERMAL PAIN-RELATED AND
SMALL MOLECULE DRUG DELIVERY
The transdermal pain-related drug delivery market is
conservatively estimated in excess of $5 billion
worldwide and is projected to grow at a 12% annual
pace. However, there are currently two major limitations
with transdermal pain-related delivery systems - long lag
time to action and dosage limits of about 10 mg.

Current transdermal technology cannot successfully
deliver all small molecule drugs for a variety of reasons
besides molecular size, such as ionic state, solubility,
melting point, and potency. It is expected that the
DrugMAT will facilitate transdermal delivery of some of
these small molecule drugs, which cannot currently be
transdermally delivered.
PROTEIN DRUG DELIVERY
VACCINE DELIVERY
TRANSDERMAL PAIN-RELATED AND
SMALL MOLECULE DRUG DELIVERY